The difference in 503A vs 503B compounding comes down to oversight and how a facility operates. A 503A pharmacy compounds for individual patients under a prescription, and its state board of pharmacy oversees it. A 503B outsourcing facility registers with FDA, must follow federal manufacturing standards, and can compound in batches with or without patient-specific prescriptions. Neither type produces FDA-approved drugs.

Key takeaways

503A vs 503B: the short answer

A 503A pharmacy compounds medications for named patients and is overseen mainly by its state. A 503B outsourcing facility is registered with FDA, held to manufacturing-grade standards, and allowed to make batches.

Compounding means preparing a medication by combining or altering ingredients, usually to meet a need a standard product does not. Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) covers a licensed pharmacist in a state-licensed pharmacy or federal facility, or a licensed physician, not registered with FDA as an outsourcing facility. Section 503B covers compounding inside an outsourcing facility by or under the direct supervision of a licensed pharmacist, and the facility does not have to be a licensed pharmacy (FDA, 2021). That is why "outsourcing facility" is the accurate term, not "503B pharmacy."

Feature503A pharmacy503B outsourcing facility
PrescriptionsBased on a valid prescription for an identified patientMay or may not obtain patient-specific prescriptions
Main day-to-day oversightState board of pharmacyFDA, on a risk-based inspection schedule
cGMP requiredNo (exempt)Yes
Bulk ingredientsUSP/NF monograph if one exists, plus USP compounding chapterMust be on the 503B bulks list, or the drug must be on FDA's shortage list
Adverse-event reporting to FDANot federally requiredSpecific reporting requirements
Interstate distributionLimited, depending on the state's agreement with FDANo explicit condition
FDA-approved productsNoNo

The split tells you who oversees a facility and how it operates. It does not certify any individual vial.

Who oversees each, and what cGMP adds

FDA is the primary overseer of 503B outsourcing facilities. For 503A pharmacies, state boards of pharmacy have primary responsibility, and FDA conducts surveillance and for-cause inspections (FDA Q&A, 2025).

Congress created the outsourcing facility category in 2013 through the Drug Quality and Security Act (FDA Q&A, 2025). The key legal difference is cGMP. Drugs compounded under all 503A conditions are exempt from cGMP requirements. Drugs compounded under all 503B conditions are not, although both categories are exempt from new drug approval and from labeling with adequate directions for use (FDA, 2021).

cGMP is the set of federal quality rules drug manufacturers follow, covering areas such as process control, testing and record-keeping. Without that requirement, 503A quality standards come largely from state law and USP, the organization that publishes official standards for medicines.

Adverse-event reporting also differs. Outsourcing facilities have specific reporting requirements (FDA 503B guidance). State-licensed pharmacies that are not outsourcing facilities have no federal duty to report adverse events to FDA, so FDA says adverse events from compounded GLP-1 drugs are likely underreported (FDA GLP-1 concerns, 2026).

Patient-specific versus batch compounding

A 503A pharmacy compounds against prescriptions for identified patients. An outsourcing facility can make batches before any specific patient is named.

Under 503A, compounding must be based on a valid prescription for an identified individual patient, either after it arrives or in limited quantities beforehand. An outsourcing facility may or may not obtain patient-specific prescriptions (FDA, 2021). That flexibility is what allows batch production.

Both sections regulate the bulk drug substance, the raw active ingredient a compounder starts from. Under both, it must come with a valid certificate of analysis (COA), the manufacturer's test report for that lot, and be made by an FDA-registered establishment. A 503B facility faces a different gate: the substance must appear on FDA's 503B bulks list, which identifies the bulk substances outsourcing facilities may use, or the drug must be on FDA's shortage list when it is compounded, distributed and dispensed (FDA, 2021; FDA, 2026).

Neither model may act as a shadow drug manufacturer. A 503A compounder may not regularly, or in inordinate amounts, compound essentially copies of commercially available products, and 503B drugs may not be essentially copies of approved drugs (FDA, 2021).

Is 503B better than 503A?

FDA says there are greater assurances of quality when drugs come from outsourcing facilities that meet 503B conditions and cGMP than from entities not required to follow cGMP and not routinely overseen by FDA (FDA 503B guidance). That is a statement about systems, not about the specific product you receive.

FDA adds that outsourcing-facility drugs, like all compounded drugs, have not undergone premarket review for safety, effectiveness and quality, and lack the premarket inspection and manufacturing-quality finding that is part of drug approval (FDA 503B guidance). An inspection is also a snapshot in time: a recent satisfactory one gives some assurance that conditions met cGMP then, but conditions can change. Inspections are facility-specific, so two sites under the same owner are inspected separately (FDA registration Q&A).

Risk exists in both models. Poor compounding practices can cause contamination or a drug with too much or too little active ingredient, which can lead to serious injury and death (FDA Q&A, 2025).

So "the two are equal in quality" is not what FDA says, and neither is "every batch-made vial is perfect." The useful question is about the actual facility that made your medication.

Why compounded drugs are not FDA-approved

Compounded drugs from a 503A pharmacy or a 503B outsourcing facility are not FDA-approved. Drugs compounded under the conditions of either section are exempt from new drug approval requirements, and FDA does not verify their safety, effectiveness or quality before they are marketed (FDA, 2021; FDA Q&A, 2025).

When a patient can use an available FDA-approved drug, FDA recommends that practitioners prescribe it (FDA registration Q&A). FDA also says compounded drugs serve an important role for patients whose needs an approved drug cannot meet, such as someone with a dye allergy, while noting they can pose a higher risk to patients (FDA 503B guidance). Whether a compounded or an approved product fits a particular person is a decision for a licensed clinician.

FDA raises two specific concerns. The first is a telehealth company claiming a compounded drug, which is not FDA-approved, is the same as an FDA-approved drug. The second is the use of salt forms such as semaglutide sodium or semaglutide acetate, which FDA says are different active ingredients from those in the approved drugs (FDA GLP-1 concerns, 2026). Our guide to semaglutide sodium vs base covers what to ask.

The April 2026 FDA proposal on GLP-1s and the 503B bulks list

On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, saying it found no clinical need for outsourcing facilities to compound them from bulk drug substances (FDA, 2026).

FDA said it reviewed the nominations and did not find sufficient evidence to include the three substances, and that a clinical-need determination rests on patient safety and medical necessity under the law. Commissioner Makary said, in substance, that when FDA-approved drugs are available, outsourcing facilities cannot lawfully make these drugs from bulk substances without a clear clinical need. The original comment deadline was June 29, 2026, and FDA said it would consider comments before making a final determination (FDA, 2026).

The proposal is not a rule about 503A pharmacies, which operate under separate conditions (FDA, 2021). Proposals can change after public comment, so check FDA's press announcements and the Federal Register for current status before relying on any summary, this one included.

One thing does not change with the regulatory outcome. People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2), or a history of pancreatitis, should not use these medications, and a licensed clinician screens for this. Our review of semaglutide pancreatitis risk covers the trial and label data.

What to ask about where your compounded medication is made

Ask about the specific facility that made your medication, not the category. The answers are short and checkable.

  1. Was it made by a 503A pharmacy or a 503B outsourcing facility, and what is the facility's name and location?
  2. If a 503A pharmacy, is it licensed by your state board of pharmacy?
  3. If a 503B facility, is it registered with FDA, and what does its record show? FDA's compounding inspections, recalls and other actions page labels entries by facility type and can list Form 483s, which are observations investigators may issue after an inspection, and de-registration status (FDA inspections page, 2026).
  4. For a GLP-1, is the active ingredient the base form or a salt form that FDA flags?
  5. Does the bulk ingredient come with a certificate of analysis from an FDA-registered manufacturer?
  6. Who do you contact about a side effect or quality concern?

Also watch for FDA's packaging red flags: medicine that looks different than expected, arrives damaged, or comes without instructions (FDA GLP-1 concerns, 2026). Our free compounded source verification checklist walks through these checks.

How access works through New Blue

New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.

  1. You complete a structured intake.
  2. A licensed clinician reviews it. Some treatments or states may require a live visit, and every testosterone or hormone pathway requires a live clinician visit plus lab work.
  3. If prescribed, a licensed partner pharmacy ships the medication directly to you.

Not everyone qualifies. Eligibility depends on your intake and clinical review, and that's how it should work. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities, and they are not FDA-approved. Compounded semaglutide has the same active ingredient as Ozempic and Wegovy. Compounded tirzepatide has the same active ingredient as Mounjaro and Zepbound. Neither is an equivalent or generic version of those brand products, which are FDA-approved. Our compounding disclosure has the details, and the Semaglutide GLP-1 pathway page has current pricing.

The Semaglutide and Tirzepatide GLP-1 pathways have delivery limits in some states. Availability varies by state, so check state availability. New Blue is LegitScript certified, serves adults 21 and older only, and is not for emergencies.

Frequently Asked Questions

What is a 503B outsourcing facility?

A 503B outsourcing facility is a compounder registered with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must follow cGMP, is inspected by FDA on a risk-based schedule, and may compound with or without patient-specific prescriptions. It is not required to be a licensed pharmacy.

Is 503B better than 503A?

FDA says cGMP-compliant outsourcing facilities give greater assurance of quality than compounders not held to cGMP or routinely overseen by FDA. Their drugs still get no FDA premarket review, and an inspection is only a snapshot in time. The facility that actually made your medication matters more than the label.

Does FDA approve drugs made by 503B outsourcing facilities?

No. Drugs from 503B outsourcing facilities and from 503A pharmacies are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed. FDA registration and inspection are not the same as approval.

Did FDA ban compounded semaglutide and tirzepatide in 2026?

The April 30, 2026 announcement was a proposal, not a final ban. FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, which governs what outsourcing facilities may compound from bulk ingredients. FDA said it would consider public comments before a final determination, so check FDA's press announcements for current status.

How can I check a compounding facility's FDA record?

Get the facility's name and type, then search FDA's compounding inspections, recalls and other actions page. Entries are labeled as 503A or 503B facilities and can include Form 483s and de-registration status. For a 503A pharmacy, also confirm its license with your state board of pharmacy.

Sources

  1. FD&C Act Provisions that Apply to Human Drug Compounding. U.S. Food and Drug Administration, 2021. https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding
  2. Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  3. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (press release). U.S. Food and Drug Administration, 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  4. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the FD&C Act (Guidance for Industry). U.S. Food and Drug Administration, n.d. https://www.fda.gov/media/98964/download
  5. Questions and Answers: Outsourcing Facility Registration. U.S. Food and Drug Administration, n.d. https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration
  6. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  7. Compounding: Inspections, Recalls, and other Actions. U.S. Food and Drug Administration, 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions

Medical disclaimer: This article is for educational purposes only and is not medical advice. Treatment decisions are made by a licensed clinician based on your intake and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider.

Content review & editorial standards

This page is educational content from the New Blue Health Editorial Team. It is checked under the New Blue Health Content Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.

Start Your Visit